Morgan Keegan initiated Solta Medical SLTM coverage with a Market Perform rating and $3.50 price target in a research report published after the Tuesday market close.
In the report, Morgan Keegan states, "In our opinion, Solta has a sound business model that is predicated on a market segmentation strategy, cross seling, and generating a recurring revenue stream."
Shares of Solta Medical closed Tuesday at $2.82, down 2.08% from Monday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in